Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
19 studies found for:    e1305
Show Display Options
Rank Status Study
1 Recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Major Salivary Gland Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Tongue Carcinoma;   Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary
Interventions: Drug: Docetaxel;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Fluorouracil;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Cytology Specimen Collection Procedure
2 Completed To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305
Condition: Healthy
Intervention: Drug: AZD1305
3 Completed An Interaction Study of Ketoconazole/Verapamil Versus AZD1305
Condition: Healthy
Interventions: Drug: Ketoconazole;   Drug: Verapamil;   Drug: AZD1305
4 Completed An Interaction Study With Digoxin and AZD1305
Condition: Atrial Fibrillation
Interventions: Drug: AZD1305;   Drug: Digoxin
5 Recruiting Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: aminolevulinic acid
6 Completed
Has Results
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Conditions: Venous Thromboembolism;   Deep Vein Thrombosis;   Pulmonary Embolism;   Thromboembolism;   Venous Thrombosis
Interventions: Drug: edoxaban tosylate(DU-176b);   Drug: low molecular weight heparin/unfractionated heparin;   Drug: warfarin
7 Unknown  The Effects of High and Low GI Breakfasts on Cognitive Performance in Adults With Type 2 Diabetes
Condition: Type 2 Diabetes
Intervention:
8 Active, not recruiting A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: bevacizumab;   Drug: docetaxel;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: pegfilgrastim
9 Active, not recruiting A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
Condition: Metastatic Colorectal Cancer
Interventions: Biological: cetuximab;   Drug: 5-FU;   Drug: oxaliplatin;   Drug: leucovorin
10 Active, not recruiting Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Condition: Atherosclerosis
Interventions: Drug: Canakinumab;   Drug: Placebo
11 Completed
Has Results
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium;   Drug: placebo
12 Active, not recruiting Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a vs Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Chronic Hepatitis B(CHB).
Condition: Chronic Hepatitis B
Interventions: Drug: TDF;   Drug: PEG
13 Completed
Has Results
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Conditions: Melanoma;   Skin Neoplasms
Intervention: Drug: Axitinib [AG-013736]
14 Active, not recruiting Open Label Study of Long Term Evaluation Against LDL-C Trial
Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab (AMG 145) and standard of care;   Other: Standard of care
15 Completed
Has Results
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
Condition: Cardiovascular Diseases
Interventions: Drug: Telmisartan;   Drug: Combination of Telmisartan and Ramipril;   Drug: Ramipril
16 Active, not recruiting Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Trastuzumab;   Drug: Neratinib;   Drug: Doxorubicin;   Drug: Cyclophosphamide
17 Active, not recruiting Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone
Condition: Heart Failure
Interventions: Drug: BAY94-8862;   Drug: Eplerenone;   Drug: Placebo
18 Completed Acupuncture as Pain Relief and Relaxation During Childbirth
Conditions: Acupuncture Analgesia;   Natural Childbirth
Interventions: Procedure: Acupuncture;   Other: TENS;   Other: Traditional Group
19 Recruiting A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Condition: Advanced Cutaneous Melanoma
Intervention:

Indicates status has not been verified in more than two years